This pharmaceutical and healthcare report provides information on the Lifestyle Management Strategies (LCM) market, the reasons why companies implement LCM strategies and the challenges faced by them. This report provides comprehensive analysis of five key LCM strategies (new indications, formulation variants, extended/controlled released versions, Rx-to-OTC switch and store brand generic) using case studies.

The report also provides the sales growth patterns of key drugs for which LCM activities are being carried out. It also reviews the factors determining the success and failure of the strategies providing an understanding of how to ensure success for LCM.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by our team of industry experts.


Scope

The scope of this report includes:

- Analysis and data on LCM activities of top twenty pharmaceutical companies including Roche, Bayer, GSK, and Pfizer in terms of the LCM pipeline.

- Insight into the LCM activities in the top five therapeutic areas including cancer, central nervous system (CNS), cardiovascular system (CVS), metabolic diseases and infectious diseases.

- Detailed case studies for each of the key LCM strategies identified. Sales and growth trend data for selected examples for each of the key strategies.

- Sales growth analysis of top ten drugs under LCM and the timeline of LCM events

- Qualitative analysis of market drivers, restraints, future outlook and challenges faced by the LCM strategies of the companies

- Framework for measuring LCM performance and effective team structures for integrating the LCM team into the organization


Reasons to buy

The report will enhance your decision making capability. It will allow you to

- Align product portfolio to the markets with high growth potential

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety

- Develop key strategic initiatives by understanding key focus areas of leading companies

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps

Table of Contents



85 pages

Publication Date : February 2010